XETRA:PUMG.DE 27 January 2026

May 25, 2026, 8:14 AM EDT. Grail's (GRAL) stock has fallen over 20% in 2026 after missing the primary endpoint in a major multicancer early detection (MCED) trial with England's NHS. The failed endpoint raises FDA approval and insurance reimbursement concerns. However, CEO Bob Ragusa highlighted a notable reduction in Stage IV cancer diagnoses and sustained test performance. Grail's Galleri test sales grew 37% year-on-year, driven by out-of-pocket buyers and growing clinical support. Investors await a six- to 12-month follow-up study and detailed trial data at the American Society of Clinical Oncology (ASCO) meeting in late May/early June, which could be pivotal for regulatory and commercial prospects.